As per industry analysis on tumor necrosis factor (TNF) inhibitors by Fact.MR, a market research and competitive intelligence provider, the global market is anticipated to expand at a CAGR of 1.3% over the forecast period of 2021-2027.
Tumor necrosis factor inhibitors are medications that help repair the damage that these disorders create. TNF-alpha is the first molecule in the cytokine cascade, which plays an important role in systemic inflammation, and has been linked to autoimmune disorders. TNF-alpha levels rise dramatically in the elderly population.
TNF inhibitor biosimilars are expected to open up lucrative opportunities by making tumor necrosis factor inhibitors more accessible and affordable, resulting in increased usage of tumor necrosis factor (TNF) inhibitors.
Tumor necrosis factor inhibitor manufacturers in the global market are projected to offer a wide range of drugs to treat a variety of inflammatory diseases. Some of the key factors projected to drive market revenue are rapid technological advancements and increase in global healthcare expenditure.
Download Free Sample Copy of This Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=7302
Key Takeaways from Market Study
- Global tumor necrosis factor inhibitors market to reach US$ 45.5 Bn by 2027.
- Market in China projected to reach around US$ 8.5 Bn by 2027.
- Market in Canada to record 0.8% CAGR over forecast period of 2021-2027.
- Market in Europe expected to rise at CAGR of 0.4% over forecast period.
“Emergence of advanced products and increased public awareness about technologically-advanced treatment and product development are factors anticipated to stimulate industry expansion over the coming years,” says a Fact.MR analyst
Rising prevalence of inflammatory bowel disease (IBD), increasing demand for TNF drugs, and the growing preference for biosimilars are driving the market growth in the U.S.
Key Segments Covered in TNF Inhibitors Industry Research
- By Drug Class :
- Adalimumab
- Infliximab
- Rituximab
- Others
- By Indication :
- Rheumatoid Arthritis
- Crohn’s Disease
- Psoriasis
- Others
- By Distribution Channel :
- Hospital Pharmacies
- Specialty Pharmacies
- Online Pharmacies
- By Region :
- North America TNF Inhibitors Market
- Europe TNF Inhibitors Market
- Asia Pacific TNF Inhibitors Market
- Latin America TNF Inhibitors Market
- MEA TNF Inhibitors Market
Get Customization on this Report for Specific Research Solutions – https://www.factmr.com/connectus/sample?flag=RC&rep_id=7302
Winning Strategy
Some of the most prominent players in the TNF inhibitors market are pursuing strategic goals such as mergers and acquisitions and joint ventures for product development. Furthermore, the market dynamics are highly competitive due to patent infringement difficulties amongst manufacturers.
Key players are engaged in product launches & approvals, and other future growth initiatives. These efforts are creating significant opportunities for market participants to grow their businesses.
For instance,
- In May 2020, AbbVie Inc, a biopharmaceutical corporation based in the United States, acquired the business of Allergan plc for US$ 63 Bn. AbbVie Inc’s revenue base and current immunology portfolio are projected to grow and diversify as a result of the acquisition.
Under the commercial name Humira, adalimumab is the first and only completely human monoclonal antibody licenced by the U.S. Food and Drug Administration for the treatment of rheumatoid arthritis.
Key Companies Profiled
- AbbVie Inc.
- Amgen Inc.
- Innovent Biologics, Inc.
- Novartis International AG
- Pfizer, Inc.
- Merck & Co., Inc.
- Biocad Biopharmaceutical Co.
- Boehringer Ingelheim Pharmaceuticals, Inc.
For In-Depth Competitive Analysis, Buy Now – https://www.factmr.com/checkout/7302
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global tumor necrosis factor (TNF) inhibitors market, presenting historical demand data (2017-2020) and forecast statistics for the period of 2021-2027.
The study divulges essential insights on the market on the basis of drug class (adalimumab, infliximab, rituximab, and others), indication (rheumatoid arthritis, Crohn’s disease, psoriasis, and others), and distribution channel (hospital pharmacies, specialty pharmacies, and online pharmacies), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).
Check Out More Related Studies Published By Fact.MR Research:
Throat Lozenges Market: The global throat lozenges market is expected to rise from a valuation of US$ 5.4 billion in 2022 to US$ 6.5 billion by 2026, expanding at a CAGR of 4.8% during the forecast period.
Microplate Systems Market: Worldwide sales of microplate systems are valued at US$ 922.3 million in 2022. The global microplate systems market is projected to register 4.5% CAGR to reach a valuation of US$ 1.1 billion by the end of 2026.
Doxorubicin Market: Demand for doxorubicin is anticipated to increase steadily at a CAGR of 5.3% from 2022 to 2026. At present, the global doxorubicin market stands at US$ 1.1 Billion, and are projected to reach a valuation of US$ 1.3 Billion by the end of 2026.
Induced Pluripotent Stem Cell (iPSC) Market: The global induced pluripotent stem cell (iPSC) market stands at a valuation of US$ 1.8 Bn in 2022, and is projected to climb to US$ 2.3 Bn by the end of 2026. Over the 2022 to 2026 period, worldwide demand for induced pluripotent stem cells is anticipated to rise rapidly at a CAGR of 6.6%. The China iPSC market is expected to surge ahead at a CAGR of 8.5% over the same time frame.
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: sales@factmr.com